MedTrace Logo

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

NCT01876251 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-03-15

Study results available
· View outcomes & findings →

Summary

This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.

Conditions

  • Breast Cancer Metastatic

Interventions

DRUG

PF-03084014

Tablet, 10 mg, twice a day

DRUG

PF-03084014

Tablet, 50 mg, twice a day

DRUG

PF-03084014

Tablet, 100 mg, twice a day

DRUG

Docetaxel

Solution for IV infusion 75 mg/m\^2, every 3 weeks

DRUG

Docetaxel

Solution for IV infusion 100 mg/m\^2, every 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-04
Primary Completion
2015-12-24
Completion
2015-12-24

Countries

  • United States
  • Belgium
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01876251 on ClinicalTrials.gov